Foresee Pharmaceuticals Co Ltd Asset Resilience Ratio
Foresee Pharmaceuticals Co Ltd asset resilience ratio. Foresee Pharmaceuticals Co Ltd (6576) has an Asset Resilience Ratio of 4.79% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Foresee Pharmaceuticals Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Foresee Pharmaceuticals Co Ltd (2019–2024)
Asset resilience ratio of Foresee Pharmaceuticals Co Ltd from 2019 to 2024. This chart shows how Foresee Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. Read Foresee Pharmaceuticals Co Ltd (6576) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Foresee Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Foresee Pharmaceuticals Co Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$75.00 Million | 4.79% |
| Total Liquid Assets | NT$75.00 Million | 4.79% |
Asset Resilience Insights
- Limited Liquidity: Foresee Pharmaceuticals Co Ltd maintains only 4.79% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Foresee Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Foresee Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Foresee Pharmaceuticals Co Ltd Asset Resilience Ratio by Year (2019–2024)
Foresee Pharmaceuticals Co Ltd asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Foresee Pharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.47% | NT$75.00 Million ≈ $2.36 Million |
NT$2.16 Billion ≈ $68.03 Million |
-14.93pp |
| 2023-12-31 | 18.40% | NT$342.50 Million ≈ $10.79 Million |
NT$1.86 Billion ≈ $58.65 Million |
-5.81pp |
| 2021-12-31 | 24.21% | NT$397.46 Million ≈ $12.52 Million |
NT$1.64 Billion ≈ $51.71 Million |
+1.51pp |
| 2020-12-31 | 22.70% | NT$476.68 Million ≈ $15.02 Million |
NT$2.10 Billion ≈ $66.15 Million |
+17.93pp |
| 2019-12-31 | 4.77% | NT$48.16 Million ≈ $1.52 Million |
NT$1.01 Billion ≈ $31.80 Million |
-- |
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release … Read more